Citizens Financial Group Inc RI Buys New Stake in NeoGenomics, Inc. (NASDAQ:NEO)

Citizens Financial Group Inc RI purchased a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 3,875 shares of the medical research company’s stock, valued at approximately $107,000.

A number of other institutional investors also recently modified their holdings of the business. FineMark National Bank & Trust increased its stake in NeoGenomics by 1.6% during the 4th quarter. FineMark National Bank & Trust now owns 29,308 shares of the medical research company’s stock valued at $857,000 after purchasing an additional 450 shares in the last quarter. Global Retirement Partners LLC increased its stake in NeoGenomics by 27.1% during the 1st quarter. Global Retirement Partners LLC now owns 2,110 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 450 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in NeoGenomics by 0.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 83,135 shares of the medical research company’s stock valued at $2,432,000 after purchasing an additional 614 shares in the last quarter. Fifth Third Bancorp increased its stake in NeoGenomics by 5.1% during the 1st quarter. Fifth Third Bancorp now owns 14,127 shares of the medical research company’s stock valued at $390,000 after purchasing an additional 683 shares in the last quarter. Finally, Sowell Financial Services LLC increased its stake in NeoGenomics by 66.1% during the 4th quarter. Sowell Financial Services LLC now owns 1,742 shares of the medical research company’s stock valued at $51,000 after purchasing an additional 693 shares in the last quarter. Institutional investors and hedge funds own 86.77% of the company’s stock.

Shares of NASDAQ NEO opened at $28.18 on Friday. The company’s fifty day moving average price is $27.58 and its 200 day moving average price is $28.17. NeoGenomics, Inc. has a 1 year low of $18.52 and a 1 year high of $34.97. The company has a market capitalization of $2.93 billion, a PE ratio of 214.00 and a beta of 0.79. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.88 and a current ratio of 3.18.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, April 28th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.02 by ($0.04). The firm had revenue of $106.03 million for the quarter, compared to analysts’ expectations of $106.03 million. NeoGenomics had a return on equity of 2.94% and a net margin of 0.82%. The business’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period last year, the company posted ($0.03) earnings per share. On average, equities analysts expect that NeoGenomics, Inc. will post -0.12 EPS for the current year.

A number of analysts have recently weighed in on the stock. Stephens assumed coverage on shares of NeoGenomics in a research note on Tuesday, April 21st. They issued an “overweight” rating and a $33.00 price objective on the stock. Craig Hallum assumed coverage on shares of NeoGenomics in a research note on Monday, March 2nd. They issued a “buy” rating and a $38.00 price objective on the stock. Raymond James increased their price objective on shares of NeoGenomics from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. SVB Leerink reiterated a “buy” rating and issued a $35.00 price objective (up previously from $33.00) on shares of NeoGenomics in a research note on Wednesday, April 29th. Finally, Benchmark increased their price objective on shares of NeoGenomics from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $29.67.

In other NeoGenomics news, insider Robert J. Shovlin sold 98,093 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $30.86, for a total transaction of $3,027,149.98. Following the transaction, the insider now directly owns 249,733 shares of the company’s stock, valued at $7,706,760.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Steven C. Jones sold 297,300 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $28.77, for a total transaction of $8,553,321.00. Following the transaction, the director now directly owns 195,234 shares in the company, valued at $5,616,882.18. The disclosure for this sale can be found here. Company insiders own 6.50% of the company’s stock.

NeoGenomics Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Read More: Moving Average (MA)

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.